Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| ID | DOID:3078 |
| Name | anaplastic astrocytoma |
| Definition | A malignant astrocytoma that is characterized by cells with regular, round to oval nuclei. |
| Source | DiseaseOntology.org |
| Alt Ids | |
| Path | disease disease of cellular proliferation cancer cell type cancer high grade glioma malignant astrocytoma anaplastic astrocytoma |
| Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
|---|---|---|---|---|
| IDH1 R132H | Azacitidine | anaplastic astrocytoma | sensitive | detail... |
| IDH1 mutant | N/A | anaplastic astrocytoma | not applicable | detail... |
| IDH2 mutant | N/A | anaplastic astrocytoma | not applicable | detail... |
| BRAF V600E | Dabrafenib + Trametinib | anaplastic astrocytoma | sensitive | detail... |
| BRAF V600E | Cobimetinib + Vemurafenib | anaplastic astrocytoma | sensitive | detail... |
| BRAF V600E | Vemurafenib | anaplastic astrocytoma | predicted - sensitive | detail... |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02052778 | Phase Ib/II | Futibatinib | A Study of TAS-120 in Patients With Advanced Solid Tumors | Completed | USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUS | 4 |
| NCT02062827 | Phase I | M032 | Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma (M032-HSV-1) | Active, not recruiting | USA | 0 |
| NCT02658279 | Phase I | Pembrolizumab | Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype | Active, not recruiting | USA | 0 |
| NCT02800486 | Phase II | Cetuximab | Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA | Recruiting | USA | 0 |
| NCT03128047 | Phase I | Bevacizumab + Temozolomide | HUMC 1612: Optune NovoTTF-200A System | Completed | USA | 0 |
| NCT03224104 | Phase I | Radiotherapy + Zotiraciclib Temozolomide + Zotiraciclib Zotiraciclib | Study of TG02 in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma (STEAM) | Completed | NLD | FRA | DEU | CHE | AUT | 0 |
| NCT03581292 | Phase II | Temozolomide + Veliparib Veliparib | Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations | Active, not recruiting | USA | NZL | CAN | AUS | 1 |
| NCT03657576 | Phase I | C134-HSV-1 | Trial of C134 in Patients With Recurrent GBM (C134-HSV-1) | Active, not recruiting | USA | 0 |
| NCT03893487 | Phase I | CUDC-907 | Fimepinostat in Treating Brain Tumors in Children and Young Adults (PNOC016) | Active, not recruiting | USA | CHE | 0 |
| NCT03911388 | Phase I | HSV-1 G207 | HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors | Recruiting | USA | 0 |
| NCT04047303 | Phase I | CC-90010 | CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma | Terminated | USA | ESP | 0 |
| NCT04295759 | Phase I | INCB7839 | INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas | Completed | USA | 0 |
| NCT04482933 | Phase II | HSV-1 G207 | HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma | Suspended | USA | 0 |
| NCT04541082 | Phase I | ONC206 | Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms | Recruiting | USA | 0 |
| NCT04655404 | Phase I | Larotrectinib | A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma with NTRK Fusion | Recruiting | USA | DEU | CAN | AUS | 0 |
| NCT04691960 | Phase II | Metformin | A Pilot Study of Ketogenic Diet and Metformin in Glioblastoma: Feasibility and Metabolic Imaging | Recruiting | USA | 0 |
| NCT04704154 | Phase II | Nivolumab + Regorafenib | A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors | Completed | USA | ITA | GBR | FRA | BEL | 3 |
| NCT04809805 | Phase I | BAY2666605 | A Study to Learn How Safe BAY2666605 is, How it Affects the Body, How it Moves Into, Through and Out of the Body, the Maximum Amount That Can be Given and Its Action Against Tumors in Adult Participants With Skin Cancer That Has Spread to Other Parts of the Body and Other Types of Advanced Cancer | Terminated | USA | 0 |
| NCT04978727 | Phase I | SurVaxM | A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma | Active, not recruiting | USA | CAN | 0 |
| NCT05004116 | Phase Ib/II | Irinotecan + Repotrectinib + Temozolomide | A Study of Repotrectinib in Combination with Chemotherapy in Children and Young Adults with Solid Tumor Cancer | Recruiting | USA | 0 |
| NCT05084430 | Phase Ib/II | M032 + Pembrolizumab | Study of Pembrolizumab and M032 (NSC 733972) | Recruiting | USA | 0 |
| NCT05096481 | Phase II | PEP-CMV + Temozolomide | PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma | Recruiting | USA | 0 |
| NCT05429502 | Phase Ib/II | Ribociclib + Temozolomide + Topotecan | Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors | Terminated | USA | ITA | GBR | DEU | 0 |
| NCT05503797 | Phase II | PLX8394 | A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations | Recruiting | USA | SWE | NOR | ITA | GBR | FRA | ESP | DEU | CAN | AUS | 1 |
| NCT05686798 | Phase I | Ad5-yCD/mutTK(SR39)rep-ADP | Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma. | Recruiting | USA | 0 |
| NCT05698524 | Phase I | Abexinostat + Temozolomide | A Study of Temodar With PCI-24781 for Patients With Recurrent Glioma | Recruiting | USA | 0 |
| NCT05956821 | Phase Ib/II | Bevacizumab + Cetuximab | Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age | Recruiting | USA | 0 |
| NCT06011109 | Phase Ib/II | Bevacizumab APG-157 | Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab | Recruiting | USA | 0 |
| NCT06193174 | Phase I | C134-HSV-1 | Re-Administration of C134 in Patients With Recurrent GBM (C134-HSV-1) | Enrolling by invitation | USA | 0 |
| NCT06264388 | Phase II | Toca FC + Vocimagene amiretrorepvec | DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma | Recruiting | USA | 0 |
| NCT06413706 | Phase II | Abemaciclib + Temozolomide Temozolomide | A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy | Recruiting | USA | ROU | NLD | ITA | FRA | ESP | DNK | BEL | AUS | 1 |
| NCT06463184 | Phase I | Xevinapant | Study to Assess Xevinapant in Preoperative Subjects With Recurrent High-Grade Glioma (rHGG) | Withdrawn | 0 | |
| NCT06501911 | Phase I | Bicalutamide | A Study of Bicalutamide With Brain Re-irradiation to Treat Recurrent/Progressive High Grade Glioma | Withdrawn | USA | 0 |
| NCT06639607 | Phase Ib/II | Nivolumab + PEP-CMV + Temozolomide | PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma (PRiME II) | Not yet recruiting | USA | 0 |